“

Regulators have to weigh risk and benefit. And in this case, we know a lot about the risks in older individuals, and they're very low, including older children, it doesn't have to be that great, as long as we have something that's safe, and then a theoretical benefit could be that you are set up well for future vaccines. But having said all that, it does seem like a very unusual route to take.